[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100260475":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":10,"responsibleParty":16,"collaborators":10,"id":18,"slug":19,"hasResults":20,"nctId":21,"briefTitle":22,"officialTitle":23,"acronym":24,"eligibilityCriteria":25,"healthyVolunteers":26,"sex":27,"minAge":28,"maxAge":29,"enrollmentInfo":30,"targetDuration":10,"studyType":33,"phases":10,"briefSummary":34,"conditions":35,"keywords":38,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":10},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants With Chronic Hepatitis C Genotype 1",null,"Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir\u002Fr - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.",[13],{"name":14,"affiliation":5,"role":15},"Andrey Strugovschikov, MD","STUDY_DIRECTOR",{"type":17,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100260475","observational-multi-center-study-of-the-real-world-evidence-of-the-effectiveness-of-paritaprevirr---ombitasvir--dasabuvir--ribavirin-in-patients-with-chronic-hepatitis-c-in-the-russian-federation-100260475",true,"NCT02669940","Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir\u002Fr - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","Real World Evidence of the Effectiveness of Paritaprevir\u002Fr - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study","HCV RWE","Inclusion Criteria:\n\nPatients are eligible for observation in this cohort if the following applies:\n\n* Treatment-naïve or -experienced adult male or female patients with confirmed chronic hepatitis C, genotype 1, receiving combination therapy with paritaprevir\u002Fr - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label\n* If RBV is co-administered with paritaprevir\u002Fr - ombitasvir with or without dasabuvir, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)\n* Patients must voluntarily sign and date informed consent prior to inclusion into the study\n\nExclusion Criteria:\n\n* Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial",false,"ALL","18 Years","99 Years",{"count":31,"type":32},158,"ACTUAL","OBSERVATIONAL","This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir \u002Fritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin (RBV) in participants with chronic hepatitis C in a real life setting across clinical practice populations.",[36,37],"Chronic Hepatitis C","Genotype 1",[39,40,41],"Ombitasvir","Dasabuvir","Paritaprevir","COMPLETED","2018-10-18",{"date":45,"type":32},"2018-11-14",{"date":47,"type":32},"2016-04-15",{"date":49,"type":32},"2017-07-04",{"name":5,"class":6}]